Introduction
============

Mitral valve prolapse (MVP), a clinical entity that has been described in the medical literature for over a century, has undergone significant changes in its name, diagnostic criteria, and management approach.[@b1-ijgm-12-055],[@b2-ijgm-12-055] MVP impacts \~7.8 million individuals in the USA and over 176 million people worldwide.[@b2-ijgm-12-055] Echocardiography is established as the gold standard for diagnosing MVP and evaluating its hemodynamic sequel.[@b3-ijgm-12-055] The diagnostic criteria consist of billowing of one or both mitral leaflets at least 2 mm beyond the echocardiographic parasternal long-axis annular plane.[@b4-ijgm-12-055] Mitral leaflets can further be categorized as myxomatous or redundant if the thickness is 5 mm or more.[@b5-ijgm-12-055] These valvular abnormalities are associated with significant clinical complications such as congestive heart failure, bacterial endocarditis, cerebral emboli, arrhythmias, and sudden death,[@b6-ijgm-12-055]--[@b10-ijgm-12-055] which significantly alters prognosis. MVP is the most common cardiac valvular abnormality in industrialized countries and the leading cause for nonischemic and isolated mitral regurgitation (MR) requiring surgical intervention.[@b11-ijgm-12-055]--[@b13-ijgm-12-055] In addition, diagnosis of MVP may cause untold societal burden due to associated anxiety, which may impact individuals' personal and professional life.[@b11-ijgm-12-055]

In early research on MVP, the prevalence in the general population varied between 5% and 15%, reaching up to 35% in some studies.[@b14-ijgm-12-055] This variation was likely due to technological limitations and poorly defined criteria used for diagnosis.[@b15-ijgm-12-055] With the implementation of the currently modified criteria of MVP and an improved understanding of mitral valve anatomy, the published prevalence of MVP has significantly decreased.[@b14-ijgm-12-055],[@b15-ijgm-12-055] In accordance, the Framingham Heart Study reported an overall prevalence of 2%--3%.[@b15-ijgm-12-055] However, there is still a variation in MVP prevalence across studies, which may be due to methodical differences in study design or population differences secondary to the variation in genetic and environmental predispositions.[@b11-ijgm-12-055],[@b16-ijgm-12-055] Studies by Flack et al and Hepner et al estimated MVP prevalence of \<1%, which is significantly lower than the prevalence reported in the Framingham Heart Study.[@b16-ijgm-12-055],[@b17-ijgm-12-055] The MELEN study concluded the prevalence to be only 0.36% in their population.[@b18-ijgm-12-055] In Saudi Arabia, a study conducted at King Abdulaziz Medical City revealed a prevalence of 0.33%, which is less than previously published results from studies conducted in Saudi Arabia.[@b19-ijgm-12-055]--[@b22-ijgm-12-055]

To the best of our knowledge, the prevalence and characteristics of MVP have not been studied at King Abdulaziz University Hospital since 1992.[@b23-ijgm-12-055] Therefore, in light of the scarcity of current research regarding this topic in the Saudi population, and specifically in this hospital, we aimed to determine the prevalence and characteristics of MVP in a tertiary care center experience here at King Abdulaziz University Hospital in Jeddah.

Materials and methods
=====================

A retrospective chart review was conducted at King Abdulaziz teaching hospital in Jeddah, Saudi Arabia. All medical records of patients with cardiac diseases who were admitted to the hospital during the 11-year period from 2007 to 2017 were reviewed, and all patients with an echocardiography-confirmed diagnosis of MVP were recruited to the study. The echocardiographic diagnostic criteria for MVP considered for recruitment of patients for this study were superior displacement of mitral valve leaflets 2 mm or more toward the left atrial (LA) cavity during systole and a valve leaflet thickness of at least 5 mm.[@b24-ijgm-12-055] There were no exclusion criteria for recruitment, and all ages were eligible. The data sheet used to collect information from the medical record included demographic data (such as age, sex, body mass index \[BMI\], and nationality), clinical presentations (including chest pain, palpitation, dyspnea, syncope, or asymptomatic presentation), risk factors and associated comorbidities (such as skeletal deformities, connective tissue diseases, diabetes mellitus, hypertension, and dyslipidemia), and echocardiographic findings (including left ventricular end-diastolic dimension \[LVd\], left ventricular end-systolic dimension \[LVESD\], left ventricular \[LV\] dimension fraction shortening \[FS\], LA size, and ejection fraction \[EF\]).

All demographic, clinical, and echocardiographic data were analyzed using IBM SPSS software version 20.0 (IBM Corporation, Armonk, NY, USA). Categorical variables were described using frequencies and percentages, and quantitative variables were presented using mean, range, and SD. Correlations between various demographic, clinical, and echocardiographic variables were carried out using the Spearman rank correlation test. Comparison between cardiac symptoms and gender was done by the chi-squared test. Comparison between cardiac symptoms and age groups was done by one-way ANOVA. Again, the one-way ANOVA tests were used to compare valve leaflet types and MR degree to echocardiogram parameters. Significance of the analyzed data was set at 95% CI and 5% probability value level.

This study was approved by the Unit of Biomedical Ethics Research Committee at King Abdulaziz University, and it was conducted in accordance with the Declaration of Helsinki. Patient consent to review their medical records was not required by the ethics committee. This waiver was due to the retrospective chart review nature of our study. No personal data that could reveal a patient entity were used. Patient data were strictly protected for confidentiality when conducting this study.

Results
=======

A total of 97 patients with echocardiography-confirmed MVP were included in the retrospective chart review. The mean age of the patients included in this study was 43.82±16.16 years with a range of 17 and 94 years. Two-thirds of the patients (67.0%) were females and a majority (55.7%) were citizens of Saudi Arabia. The mean BMI of the studied patients was 24.97±6.27 kg/m^2^ with a range of 14.21 and 56.14 kg/m^2^ ([Table 1](#t1-ijgm-12-055){ref-type="table"}).

The main cardiac risk factors in the studied population were hypertension, diabetes mellitus, and dyslipidemia found in 19.6%, 5.2%, and 5.2% of the patients, respectively. None of the patients had scoliosis, other skeletal disorders, thyroid disorder, or a history of rheumatic fever. One patient each had a medical history significant for Marfan syndrome, Down's syndrome, and congenital heart disease. HIV+ status and hypereosinophilic syndrome were each noted in a single patient.

The clinical presentations of MVP were chest pain, palpitations, dyspnea, and syncope found in 23.7%, 11.3%, 9.3% and 5.2% cases, respectively. Among the 32 male patients in this study, 8 (25.0%) had chest pain, 3 (9.4%) had palpitations, 4 (12.5%) had dyspnea, and 1 (3.1%) had syncope. Among the 65 female patients in this study, 15 (23.1%) had chest pain, 8 (12.3%) had palpitations, 5 (7.7%) had dyspnea, and 4 (6.2%) had syncope. None of the recruited patients had an asymptomatic presentation of MVP. The chi-squared test revealed no statistically significant difference between males and females in terms of clinical presentation ([Table 2](#t2-ijgm-12-055){ref-type="table"}). A total of 22 patients were diagnosed at age 30 years or younger. Among this group, five (22.7%) had chest pain, three (13.6%) had palpitations, three (13.6%) had dyspnea, and one (4.5%) had syncope. Sixty patients were diagnosed between ages 31 and 60 years. Fifteen (25.0%) had chest pain, eight (13.3%) had palpitations, five (8.3%) had dyspnea, and two (3.3%) had syncope. The number of patents aged 61 years and older (maximum age =94 years) was 15. Only 3 of them (20.0%) had chest pain, 14 (93.3%) had palpitations, 1 (6.7%) had dyspnea, and 2 (13.3%) had syncope. There was no statistically significant difference between the age groups in terms of chest pain, palpitations, dyspnea, or syncope ([Table 3](#t3-ijgm-12-055){ref-type="table"}).

In almost half of the patients' files (47.4%), there was no clear indication for requesting an echocardiography beyond the health care provider's documented request. Among the remaining half, echocardiography was indicated for clinical suspicion of MVP in 17 (17.5%) cases and for chest pain in 9 (9.3%) cases. With regard to the echocardiographic parameters, the mean LVd for all patients was 4.93±0.68 cm, the mean LVESD was 3.20±0.55 cm, the mean EF was 63.43%±7.88%, the mean FS was 34.84±5.91 cm, and the mean LA size was 3.60±0.79 cm ([Table 4](#t4-ijgm-12-055){ref-type="table"}). Only one patient had mitral stenosis. There was a variety of prolapse types: 54.6% had anterior mitral leaflet prolapse, 27.8% had posterior leaflet prolapse, and 17.5% had both leaflets prolapsed. Flail leaflet was noticed in 5.2% of the cases, but none of the patients had ruptured chordae. The degree of the MR was trivial in 13.4%, mild in 45.4%, moderate in 32.0%, and severe in 7.2% of the recruited patients. Almost one-third of the patient (32.0%) had a thickened mitral valve leaflet. One patient had LV hypertrophy, whereas none had decreased LV systolic function. Mild increase in LV internal cavity was reported in 5.2% cases, while a severe increase was reported in 4.1% cases ([Table 5](#t5-ijgm-12-055){ref-type="table"}). The correlations between different demographic, clinical, and echocardiographic variables are detailed in [Table 6](#t6-ijgm-12-055){ref-type="table"}.

When echocardiographic parameters were compared across the leaflet types, we observed a statistically significant difference in LVd (*P*\<0.001), LVESD (*P*=0.008), and LA size (*P*\<0.001). Of note, the posterior leaflet type was associated with the highest values of LVd, LVESD, and LA size. EF and FS were statistically similar across different leaflet types ([Table 7](#t7-ijgm-12-055){ref-type="table"}). In contrast, LVd (*P*\<0.001), LVESD (*P*\<0.001), and LA size (*P*\<0.001) were significantly different across different degrees of MR. Moderate and severe degrees of MR were associated with higher LVd, LVESD, and larger LA size, whereas there was no statistically significant difference in EF and FS across degrees of MR ([Table 8](#t8-ijgm-12-055){ref-type="table"}).

Discussion
==========

In this retrospective review, 97 patients were identified with MVP, with a mean age of 43.82±16.16 years. MVP often occurs in adulthood and increases with age. Aging is associated with degenerative changes in the valvular leaflets and therefore, higher rates of valve prolapse. In this study, the mean age of diagnosis is higher than what is reported among various literature.[@b13-ijgm-12-055],[@b14-ijgm-12-055] This may be due to different sample characteristics, and it may also reflect a selection bias as it will be noted at the end of discussion. In this study, we identified age as a significant correlate of worse echocardiographic parameters, namely LVd and LA size (*P*\<0.05). Females constituted the vast majority of the patients, which is in agreement with the medical literature that reports a higher prevalence in women.[@b25-ijgm-12-055],[@b26-ijgm-12-055] Although females have milder grades of mitral prolapse and lower rates of surgical interventions, they suffer from higher mortality rates.[@b25-ijgm-12-055] We noted similar results in this study as gender was significantly correlated with the echocardiographic measures, specifically LVd, LVESD, and LA size. The mechanisms behind this gender differences in MVP remain elusive.

Acquired MVP can present secondary to various etiologies. The most common is myxomatous degeneration, due to deposition of proteoglycans in the mitral valve leaflets. This primarily affects patients with connective tissue diseases or advanced age. The next most common are inflammatory etiologies, with rheumatoid heart disease serving as the prototype disease leading to MVP. In this study, the majority of the recruited patients had a BMI within normal range, with a mean of 24.9±6.27 kg/m^2^. This is similar to reports in the medical literature.[@b14-ijgm-12-055],[@b19-ijgm-12-055],[@b25-ijgm-12-055] Patients with MVP are characteristically tall and lean, which is attributed to the specific structure of connective tissue in these patients.[@b3-ijgm-12-055],[@b16-ijgm-12-055] Marfan syndrome is one of the common connective tissue diseases associated with MVP and was found in one of the studied patients.[@b27-ijgm-12-055] However, other connective tissue diseases such as Ehlers--Danlos syndrome, myxomatous disorders, Grave's disease, skeletal deformities such as scoliosis, and history of rheumatic fever were not found in our recruited subjects.

While hypertension, diabetes, and dyslipidemia were found to be commonly associated comorbidities in our study, even though they are not related to the etiology of mitral valve relapse, they may worsen the prognosis of the disease.[@b28-ijgm-12-055] Rossi et al, in their retrospective study of 814 patients with mitral valve disease, reported that these three factors were significantly associated with poor outcome and higher mortality rate.[@b29-ijgm-12-055] In the study, hypertension had a HR for mortality of 1.48 (*P*=0.01). Diabetes and hyperlipidemia were associated with HR for mortality of 1.04 (*P*\<0.001) and 1.68 (*P*=0.005), respectively. Similarly, Ernande et al reported a significant negative effect of diabetes mellitus on LV function and remodeling in patients with MVP.[@b30-ijgm-12-055] In this research, both diabetes and dyslipidemia were significantly associated with the clinical presentation of chest pain, and dyslipidemia was also associated with increased rates of palpitation and worse LV dimensions. This literature supports the poor outcome we noted in our subjects with these comorbidities.

The most common clinical presentations in our subjects were chest pain (23.7%), palpitations (11.3%), and dyspnea (9.3%), with syncope occurring in only 5.2%. Importantly, while clinical presentation varied across gender, this was not statistically significant (*P*\>0.05). Chest pain was the most common presentation in both genders, but males experienced more dyspnea and females experienced more palpitations. The difference in clinical presentation between genders is likely attributed to the anatomical differences in mitral valve leaflet position and cardiac myometrial structure.[@b31-ijgm-12-055] Age also seems to affect clinical presentation. Elderly individuals were prone to more palpitations and syncope compared with younger patients. Although similar findings are not clearly reproduced in the MVP literature, many researchers noted pathophysiologic changes that occur in mitral valve leaflets with age. The higher prevalence of syncope and palpitation in the elderly may be attributed to the scarring and tethering of the valvular leaflets and chordae and the associated alteration in valvular and ventricular geometry and function that occurs over time.[@b31-ijgm-12-055],[@b32-ijgm-12-055]

The most commonly affected leaflet in our sample was the anterior leaflet (54.6%). The posterior leaflet was affected in 27.8% and both leaflets in 17.5% of recruited patients. While involvement of the posterior leaflet was less common, it was significantly associated with increased LVESD (*P*\<0.001) and LVd (*P*=0.008) and larger LA sizes (*P*\<0.001). In reviewing the literature, anterior leaflet prolapse is more prevalent among females and is associated with mild grades of MR^2^ but confers a higher risk of residual MR after surgical valve repair.[@b33-ijgm-12-055] Concomitant MR is most predictive of poor outcome in patients with MVP.[@b34-ijgm-12-055] The majority of the recruited patients had trivial (13.4%) or mild (45.4%) MR, while moderate and severe MR was found in 32% and 7.2%, respectively. Only 1% of patients had mitral stenosis. To assess the impact of MR degree on outcomes, a comparison was made between the four grades to determine the influence on ventricular and atrial dimensions. Patients with moderate and severe MR had worse ventricular function and subsequently higher LVd, LVESD, and LA sizes (*P*\<0.001). Among the studied sample, patients with posterior leaflet MVP and severe MR had poor LV function, likely due to the higher residual LV volume and MR during systole.

The main limitation of our study is the presence of unintended selection bias. We recruited all patients who were electronically registered after admission during the period between 2007 and 2017. However, not all admitted patients were fully registered and, therefore, the sample characteristics may not be suitable for generalization. Further multicentric cross-sectional studies are recommended to identify the clinical and echocardiographic characteristics of the Saudi population.

Conclusion
==========

MVP is more prevalent among females in this Saudi population and occurs in middle-aged individuals with normal BMIs. The most common clinical presentation is chest pain, followed by palpitations and dyspnea. Males experienced more palpitation and less dyspnea than females, while the elderly presented more frequently with syncope and palpitations. However, these gender- and age-related differences were not statistically significant. The anterior leaflet was the most common leaflet prolapsed, and concomitant MR was mostly of a trivial or mild degree. Posterior leaflet mitral prolapse, while less prevalent, was significantly associated with worse LV function. Severe degrees of MR had a negative impact on LV and LA dimensions. Age, female gender, diabetes mellitus, and dyslipidemia were significantly correlated with LV and LA dimensions.
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###### 

Demographic characteristics of all patients (n=97)

  Characteristics              N (%)
  ---------------------------- -------------
                               
  Age in years (mean ± SD)     43.82±16.16
  Gender                       
   Male                        32 (33.0)
   Female                      65 (67.0)
                               
  Nationality                  
   Saudi                       54 (55.7)
   Non-Saudi                   43 (44.3)
                               
  BMI in kg/m^2^ (mean ± SD)   24.97±6.27

**Abbreviation:** BMI, body mass index.

###### 

Frequencies and percentages of chest pain, palpitation, dyspnea, and syncope in all patients (n=97), males (n=32), and females (n=65) and comparison between both gender by chi-squared test

  Symptoms      All patients (n=97), N (%)   Male (n=32), N (%)   Female (n=65), N (%)   OR      *P*-value
  ------------- ---------------------------- -------------------- ---------------------- ------- -----------
  Chest pain    23 (23.7)                    2 (25.0)             15 (23.1)              1.111   0.834
  Palpitation   11 (11.3)                    3 (9.4)              8 (12.3)               0.763   0.705
  Dyspnea       9 (9.3)                      4 (12.5)             5 (7.7)                1.778   0.413
  Syncope       5 (5.2)                      1 (3.1)              4 (6.2)                0.508   0.546

###### 

Distribution of chest pain, palpitation, dyspnea, and syncope in all patients and age categories and comparison of age categories by one-way ANOVA

  Symptoms      All patients (n=97), N (%)   Age 0--30 years (n=22), N (%)   Age 31--60 years (n=60), N (%)   Age ≥61 years (n=15), N (%)   *P*-value
  ------------- ---------------------------- ------------------------------- -------------------------------- ----------------------------- -----------
  Chest pain    23 (23.7)                    5 (22.7)                        15 (25.0)                        3 (20.0)                      0.916
  Palpitation   11 (11.3)                    3 (13.6)                        8 (13.3)                         14 (93.3)                     0.354
  Dyspnea       9 (9.3)                      3 (13.6)                        5 (8.3)                          1 (6.7)                       0.737
  Syncope       5 (5.2)                      1 (4.5)                         2 (3.3)                          2 (13.3)                      0.255

###### 

Distribution of patients according to their echocardiographic parameters (n=97)

  Parameter   Mean    SD      Min     Max
  ----------- ------- ------- ------- -------
  LVd         4.93    ±0.68   3.62    7.44
  LVESD       3.20    ±0.55   2.08    5.48
  EF          63.43   ±7.88   42.00   80.00
  FS          34.84   ±5.91   21.00   48.00
  LA size     3.60    ±0.79   2.04    5.80

**Abbreviations:** EF, ejection fraction; FS, fraction shortening; LA, left atrial; LVd, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension.

###### 

Distribution of patients according to the mitral valve-related variables (n=97)

  Variables                           Frequency   Percentage
  ----------------------------------- ----------- ------------
                                                  
  Mitral stenosis                     1           1.0
                                                  
  Prolapsed leaflet                               
   Anterior                           53          54.6
   Posterior                          27          27.8
   Both                               17          17.5
                                                  
  Flail leaflet                       5           5.2
                                                  
  Ruptured chordae                    0           0.0
                                                  
  Degree of MR                                    
   Trivial                            13          13.4
   Mild                               44          45.4
   Moderate                           31          32.0
   Severe                             7           7.2
                                                  
  Thickness of mitral valve leaflet   31          32.0
                                                  
  Decreased LVSF                      0           0.0
                                                  
  LV hypertrophy                      1           1.0
                                                  
  Increased LV internal cavity                    
   Mild                               5           5.2
   Severe                             4           4.1

**Abbreviations:** LV, left ventricle; LVSF, left ventricular systolic function; MR, mitral regurgitation.

###### 

Correlations between different demographic, clinical, and echocardiographic variables using Pearson's coefficient (at 95% CI) (n=97)

  Variable        Correlation with   *P*-value
  --------------- ------------------ -----------
                                     
  Age             BMI                0.027
  LVd             0.027              
  LA size         \<0.001            
                                     
  Gender          LVd                \<0.001
  LVESD           \<0.001            
  LA size         \<0.001            
                                     
  BMI             LVd                0.001
  LVESD           0.026              
  LA size         0.001              
                                     
  DM              Chest pain         0.002
                                     
  Dyspnea         Chest pain         0.014
  Palpitation     \<0.001            
  LVESD           0.025              
  Flail leaflet   0.016              
                                     
  LVd             LVESD              \<0.001
  LA size         \<0.001            
  Flail leaflet   \<0.001            
                                     
  LVESD           LA size            \<0.001
  Flail leaflet   \<0.001            
                                     
  LA size         Flail leaflet      0.004

**Abbreviations:** BMI, body mass index; DM, diabetes mellitus; LA, left atrial; LVd, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension.

###### 

Comparison between echocardiographic parameters and prolapsed leaflet type (n=97)

  Echo parameters   Leaflet type   Mean ± SD      95% CI         *F*      *P*-value   
  ----------------- -------------- -------------- -------------- -------- ----------- --
                                                                                      
  LVd               Anterior       4.64±0.55      4.79--4.49     13.140   \<0.001     
  Posterior         5.32±0.82      5.64--5.00                                         
  Both              5.22±0.35      5.40--5.04                                         
                                                                                      
  LVESD             Anterior       3.05±0.44      3.17--2.92     5.135    0.008       
  Posterior         3.42±0.68      3.69--3.15                                         
  Both              3.31±0.55      3.55--3.07                                         
                                                                                      
  EF                Anterior       62.61±6.86     64.50--60.72   0.680    0.509       
  Posterior         64.13±8.45     67.54--60.71                                       
  Both              64.91±9.95     70.02--59.79                                       
                                                                                      
  FS                Anterior       33.95±5.00     35.33--32.57   1.356    0.263       
  Posterior         35.74±6.35     38.25--33.23                                       
  Both              36.18±7.55     40.06--32.30                                       
                                                                                      
  LA                Anterior       3.19±0.62      3.36--3.02     22.870   \<0.001     
  Posterior         4.16±0.70      4.44--3.88                                         
  Both              3.98±0.67      4.33--3.62                                         

**Abbreviations:** EF, ejection fraction; FS, fraction shortening; LA, left atrial; LVd, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension.

###### 

Comparison between echocardiographic parameters and MR degree (n=97)

  Echo parameters   MR degree     Mean ± SD      95% CI         *F*      *P*-value
  ----------------- ------------- -------------- -------------- -------- -----------
                                                                         
  LVd               Trivial       4.68±0.53      5.00--4.36     15.748   \<0.001
  Mild              4.69±0.58     4.87--4.51                             
  Moderate          5.09±0.44     5.25--4.93                             
  Severe            6.19±0.98     7.10--5.28                             
                                                                         
  LVESD             Trivial       3.18±0.36      3.39--2.96     9.651    \<0.001
  Mild              3.03±0.50     3.18--2.88                             
  Moderate          3.23±0.39     3.38--3.09                             
  Severe            4.09±0.90     4.93--3.26                             
                                                                         
  EF                Trivial       60.55±4.73     63.41--57.69   1.395    0.250
  Mild              63.68±7.84    66.07--61.30                           
  Moderate          64.97±8.50    68.09--61.85                           
  Severe            59.85±10.40   70.76--48.94                           
                                                                         
  FS                Trivial       32.26±3.48     34.36--30.16   1.455    0.232
  Mild              34.98±5.66    36.70--33.26                           
  Moderate          36.09±6.56    38.50--33.69                           
  Severe            33.27±7.97    40.65--25.90                           
                                                                         
  LA                Trivial       3.20±0.55      3.53--2.87     18.779   \<0.001
  Mild              3.28±0.62     3.47--3.09                             
  Moderate          3.98±0.66     4.23--3.74                             
  Severe            4.87±0.67     5.49--4.26                             

**Abbreviations:** EF, ejection fraction; FS, fraction shortening; LA, left atrial; LVd, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; MR, mitral regurgitation.
